David Ternant1,2, Christophe Passot3,4, Alexandre Aubourg5, Philippe Goupille3,6, Céline Desvignes3,4, Laurence Picon5, Thierry Lecomte3,5, Denis Mulleman3,6, Gilles Paintaud3,4. 1. Laboratory of Pharmacology-Toxicology, Université François-Rabelais de Tours, CNRS, UMR 7292, CHRU de Tours, 2 Boulevard Tonnellé, 37044, Tours Cedex, France. david.ternant@univ-tours.fr. 2. Laboratory of Pharmacology-Toxicology, CHRU de Tours, Tours, France. david.ternant@univ-tours.fr. 3. Laboratory of Pharmacology-Toxicology, Université François-Rabelais de Tours, CNRS, UMR 7292, CHRU de Tours, 2 Boulevard Tonnellé, 37044, Tours Cedex, France. 4. Laboratory of Pharmacology-Toxicology, CHRU de Tours, Tours, France. 5. Department of Gastroenterology, CHRU de Tours, Tours, France. 6. Department of Rheumatology, CHRU de Tours, Tours, France.
Abstract
BACKGROUND AND OBJECTIVES: The pharmacokinetics of infliximab are highly variable and influence clinical response in chronic inflammatory diseases. The goal of this study was to build a Bayesian model allowing predictions of upcoming infliximab concentrations and dosing regimen adjustment, using only one concentration measurement and information regarding the last infliximab infusion. METHODS: This retrospective study was based on data from 218 patients treated with infliximab in Tours University Hospital who were randomly assigned to learning (two-thirds) or validation (one-third) data subsets. One-compartment pharmacokinetic and time since last dose (TLD) models were built and compared using learning and validation subsets. From these models, Bayesian pharmacokinetic and TLD models using one concentration measurement (1C-PK and 1C-TLD) were designed. The predictive performances of the 1C-TLD model were tested on two external validation cohorts. RESULTS: Pharmacokinetic and TLD models described the data satisfactorily and provided accurate parameter estimations. Comparable predictions of infliximab concentrations were obtained from pharmacokinetic versus TLD models, as well as from Bayesian 1C-PK versus 1C-TLD models. The 1C-TLD model showed satisfactory prediction of future infliximab concentrations and provided satisfactory predictions of infliximab steady-state concentration for up to three upcoming visits after a blood sample. CONCLUSIONS: Accurate individual concentration predictions can be obtained using a single infliximab concentration measurement and information regarding only the last infusion. The 1C-TLD model may help to optimize the dosing regimen of infliximab in routine therapeutic drug monitoring.
BACKGROUND AND OBJECTIVES: The pharmacokinetics of infliximab are highly variable and influence clinical response in chronic inflammatory diseases. The goal of this study was to build a Bayesian model allowing predictions of upcoming infliximab concentrations and dosing regimen adjustment, using only one concentration measurement and information regarding the last infliximab infusion. METHODS: This retrospective study was based on data from 218 patients treated with infliximab in Tours University Hospital who were randomly assigned to learning (two-thirds) or validation (one-third) data subsets. One-compartment pharmacokinetic and time since last dose (TLD) models were built and compared using learning and validation subsets. From these models, Bayesian pharmacokinetic and TLD models using one concentration measurement (1C-PK and 1C-TLD) were designed. The predictive performances of the 1C-TLD model were tested on two external validation cohorts. RESULTS: Pharmacokinetic and TLD models described the data satisfactorily and provided accurate parameter estimations. Comparable predictions of infliximab concentrations were obtained from pharmacokinetic versus TLD models, as well as from Bayesian 1C-PK versus 1C-TLD models. The 1C-TLD model showed satisfactory prediction of future infliximab concentrations and provided satisfactory predictions of infliximab steady-state concentration for up to three upcoming visits after a blood sample. CONCLUSIONS: Accurate individual concentration predictions can be obtained using a single infliximab concentration measurement and information regarding only the last infusion. The 1C-TLD model may help to optimize the dosing regimen of infliximab in routine therapeutic drug monitoring.
Authors: Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: Casper Steenholdt; Jørn Brynskov; Ole Ø Thomsen; Lars K Munck; Jan Fallingborg; Lisbet A Christensen; Gitte Pedersen; Jens Kjeldsen; Bent A Jacobsen; Anne Sophie Oxholm; Jakob Kjellberg; Klaus Bendtzen; Mark A Ainsworth Journal: Dig Dis Sci Date: 2015-02-12 Impact factor: 3.199
Authors: Wannee Kantasiripitak; An Outtier; Sebastian G Wicha; Alexander Kensert; Zhigang Wang; João Sabino; Séverine Vermeire; Debby Thomas; Marc Ferrante; Erwin Dreesen Journal: CPT Pharmacometrics Syst Pharmacol Date: 2022-06-15
Authors: Anne S Strik; Yow-Ming C Wang; Laura E Ruff; William Yashar; Bradley T Messmer; Diane R Mould Journal: AAPS J Date: 2018-09-05 Impact factor: 4.009
Authors: Ana-Marija Grišić; Maria Dorn-Rasmussen; Bella Ungar; Jørn Brynskov; Johan F K F Ilvemark; Nils Bolstad; David J Warren; Mark A Ainsworth; Wilhelm Huisinga; Shomron Ben-Horin; Charlotte Kloft; Casper Steenholdt Journal: United European Gastroenterol J Date: 2021-02-11 Impact factor: 4.623